Assessment of Cardiac Sarcoidosis with Advanced Imaging Modalities

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Orii, Makoto ^a   Imanishi, Toshio ^a   Akasaka, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; FALSE POSITIVE RESULT; HEART FUNCTION; HEART MUSCLE; HISTOPATHOLOGY; HUMAN; JAPAN; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; REVIEW; SARCOIDOSIS; CARDIOMYOPATHIES; DIAGNOSTIC USE; IMAGE ENHANCEMENT; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES;

CARDIOMYOPATHIES; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING, CINE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOIDOSIS;

EID: 84930885934     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/897956     Document Type: Review

References (96)

1. "Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999," American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 2, pp. 736-755, 1999.
2. W. C. Roberts, H. A. McAllister Jr., and V. J. Ferrans, "Sarcoidosis of the heart: A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II)," The American Journal of Medicine, vol. 63, no. 1, pp. 86-108, 1977.
3. M. C. Iannuzzi, B. A. Rybicki, and A. S. Teirstein, "Sarcoidosis," The New England Journal of Medicine, vol. 357, no. 21, pp. 2153-2108, 2007.
4. G. Hillerdal, E. Nou, K. Osterman, and B. Schmekel, "Sarcoidosis: Epidemiology and prognosis: A 15-year European study," American Review of Respiratory Disease, vol. 130, no. 1, pp. 29-32, 1984.
5. T. Morimoto, A. Azuma, S. Abe et al., "Epidemiology of sarcoidosis in Japan," European Respiratory Journal, vol. 31, no. 2, pp. 372-379, 2008.
6. L. Varron,V.Cottin,A. Schott, C. Broussolle, and P. Sève, "Lateonset sarcoidosis: A comparative study," Medicine, vol. 91, no. 3, pp. 137-143, 2012.
7. B. A. Rybicki, M. C. Iannuzzi, M. M. Frederick et al., "Familial aggregation of sarcoidosis: A Case-Control Etiologic Study of Sarcoidosis (ACCESS)," American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 11, pp. 2085-2091, 2001.
8. A. Sverrild, V. Backer, K. O. Kyvik et al., "Heredity in sarcoidosis: A registry-based twin study," Thorax, vol. 63, no. 10, pp. 894-896, 2008.
9. R. P. Baughman, E. E. Lower, and R. M. Du Bois, "Sarcoidosis," The Lancet, vol. 361, no. 9363, pp. 1111-1118, 2003.
10. L. S. Newman, C. S. Rose, E. A. Bresnitz et al., "A case control etiologic study of sarcoidosis: Environmental and occupational risk factors," The American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 12, pp. 1324-1330, 2004.
11. J. Müller-Quernheim, M. Schürmann, S. Hofmann et al., "Genetics of Sarcoidosis," Clinics in Chest Medicine, vol. 29, no. 3, pp. 391-414, 2008.
12. E. S. Chen and D. R.Moller, "Etiology of Sarcoidosis," Clinics in Chest Medicine, vol. 29, no. 3, pp. 365-377, 2008.
13. Y. Rosen, "Pathology of sarcoidosis," Seminars in Respiratory and Critical Care Medicine, vol. 28, no. 1, pp. 36-52, 2007.
14. G. Zissel, A. Prasse, and J. Müller-Quernheim, "Immunologic response of sarcoidosis," Seminars in Respiratory and Critical Care Medicine, vol. 31, no. 4, pp. 390-403, 2010.
15. E. S. Chen,Z. Song, M. H.Willett et al., "Serumamyloid a regulates granulomatous inflammation in sarcoidosis through tolllike receptor-2," American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 4, pp. 360-373, 2010.
16. A. Uemura, S. Morimoto, S. Hiramitsu, Y. Kato, T. Ito, and H. Hishida, "Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies," American Heart Journal, vol. 138, no. 2 I, pp. 299-302, 1999.
17. L. S. Newman, C. S. Rose, and L. A. Maier, "Sarcoidosis," The New England Journal of Medicine, vol. 336, no. 17, pp. 1224-1234, 1997.
18. K. J. Silverman, G. M. Hutchins, and B. H. Bulkley, "Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis," Circulation, vol. 58, no. 6, pp. 1204-1211, 1978.
19. D. Mehta, S. A. Lubitz, Z. Frankel et al., "Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing," Chest, vol. 133, no. 6, pp. 1426-1435, 2008.
20. C. Chapelon-Abric, D. de Zuttere, P. Duhaut et al., "Cardiac sarcoidosis: A retrospective study of 41 cases," Medicine, vol. 83, no. 6, pp. 315-334, 2004.
21. F. Tavora, N. Cresswell, L. Li, M. Ripple, C. Solomon, and A. Burke, "Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes," The American Journal of Cardiology, vol. 104, no. 4, pp. 571-577, 2009.
22. K. Banba, K. F. Kusano, K. Nakamura et al., "Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis," Heart Rhythm, vol. 4, no. 10, pp. 1292-1299, 2007.
23. R. Kandolin, J. Lehtonen, and M. Kupari, "Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults," Circulation: Arrhythmia and Electrophysiology, vol. 4, no. 3, pp. 303-309, 2011.
24. G. Youssef, R. S. B. Beanlands, D. H. Birnie, and P. B. Nery, "Cardiac sarcoidosis: Applications of imaging in diagnosis and directing treatment," Heart, vol. 97, no. 24, pp. 2078-2087, 2011.
25. H. Furushima, M.Chinushi,H. Sugiura,H.Kasai,T.Washizuka, and Y. Aizawa, "Ventricular tachyarrhythmia associated with cardiac sarcoidosis: Its mechanisms an outcome," Clinical Cardiology, vol. 27, no. 4, pp. 217-222, 2004.
26. M. Sekiguchi, Y. Numao, M. Imai, T. Furuie, and R. Mikami, "Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis: Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis," Japanese Circulation Journal, vol. 44, no. 4, pp. 249-263, 1980.
27. Y. Yazaki,M. Isobe,M.Hiroe et al., "Prognostic determinants of long-termsurvival in Japanese patients with cardiac sarcoidosis treated with prednisone," The American Journal of Cardiology, vol. 88, no. 9, pp. 1006-1010, 2001.
28. V. Sekhri, S. Sanal, L. J. DeLorenzo, W. S. Aronow, and G. P. Maguire, "Cardiac sarcoidosis: A comprehensive review," Archives of Medical Science, vol. 7, no. 4, pp. 546-554, 2011.
29. H. Hiraga, K. Iwai, and M. Hiroe, Guidelines for Diagnosis of Cardiac Sarcoidosis, Study Report on Diffuse Pulmonary Diseases, pp. 23-24, The Japanese Ministry of Health and Welfare, Tokyo, Japan, 1993, (Japanese).
30. "Diagnostic standard and guidelines for sarcoidosis," Japanese Journal of Sarcoidosis Granulomatous Disorders, vol. 27, pp. 89-102, 2007 (Japanese).
31. K. Soejima and H. Yada, "The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities," Journal of Cardiovascular Electrophysiology, vol. 20, no. 5, pp. 578-583, 2009.
32. H. Ohira, I. Tsujino, S. Ishimaru et al., "Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis," European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 5, pp. 933-941, 2008.
33. R. Blankstein, M. Osborne, M. Naya et al., "Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis," Journal of the American College of Cardiology, vol. 63,no. 4, pp. 329-336, 2013.
34. W. Okumura, T. Iwasaki, T. Toyama et al., "Usefulness of fasting18F-FDG PET in identification of cardiac sarcoidosis," Journal of Nuclear Medicine, vol. 45, no. 12, pp. 1989-1998, 2004.
35. S. Ishimaru, I. Tsujino, T. Takei et al., "Focal uptake on 18Ffluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis," European Heart Journal, vol. 26, no. 15, pp. 1538-1543, 2005.
36. R. Langah, K. Spicer, M. Gebregziabher, and L.Gordon, "Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis," Journal of NuclearCardiology, vol. 16,no. 5, pp. 801-810, 2009.
37. N.Tahara, A. Tahara,Y.Nitta et al., "Heterogeneousmyocardial FDG uptake and the disease activity in cardiac sarcoidosis," JACC Cardiovascular Imaging, vol. 3, no. 12, pp. 1219-1228, 2010.
38. H. Yamagishi, N. Shirai, M. Takagi et al., "Identification of cardiac sarcoidosis with 13N-NH 3/18F-FDG PET," Journal of Nuclear Medicine, vol. 44, no. 7, pp. 1030-1036, 2003.
39. O. Manabe, H. Ohira, K. Yoshinaga et al., "Elevated 18Ffluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis," European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 10, pp. 1558-1566, 2013.
40. B. A. McArdle, D. H. Birnie, R. Klein et al., "Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography?" Circulation: Cardiovascular Imaging, vol. 6, no. 5, pp. 617-626, 2013.
41. S. Greulich, C. C. Deluigi, S. Gloekler et al., "CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis," JACC: Cardiovascular Imaging, vol. 6, no. 4, pp. 501-511, 2013.
42. J. Smedema, G. Snoep, M. P. G. van Kroonenburgh et al., "Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis," Journal of the American College of Cardiology, vol. 45, no. 10, pp. 1683-1690, 2005.
43. R. J. Kim, M. R. Patel, P. J. Cawley et al., "Detection of myocardial damage in patients with sarcoidosis," Circulation, vol. 120, no. 20, pp. 1969-1977, 2009.
44. O. Vignaux, R. Dhote, D. Duboc et al., "Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: A 1-year follow-up study," Chest, vol. 122, no. 6, pp. 1895-1901, 2002.
45. T. Shimada, K. Shimada, T. Sakane et al., "Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhancedmagnetic resonance imaging.," The American Journal of Medicine, vol. 110, no. 7, pp. 520-527, 2001.
46. B. E.Hillner, B. A. Siegel, D. Liu et al., "Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry," Journal of Clinical Oncology, vol. 26, no. 13, pp. 2155-2161, 2008.
47. L. K. Shankar, J. M. Hoffman, S. Bacharach et al., "Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials," Journal of Nuclear Medicine, vol. 47,no. 6, pp. 1059-1066, 2006.
48. F. Jamar, J. Buscombe,A.Chiti et al., "EANM/SNMMI guideline for 18F-FDG use in inflammation and infection," Journal of Nuclear Medicine, vol. 54, no. 4, pp. 647-658, 2013.
49. S. Yamada, K. Kubota, R. Kubota, T. Ido, and N. Tamahashi, "High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue," Journal of Nuclear Medicine, vol. 36, no. 7, pp. 1301-1306, 1995.
50. T. Mochizuki, E. Tsukamoto, Y. Kuge et al., "FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models," Journal of NuclearMedicine, vol. 42, no. 10, pp. 1551-1555, 2001.
51. B. A. Mc Ardle, E. Leung, H. Ohira et al., "The role of F18-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patientswith known or suspected cardiac sarcoidosis," Journal of Nuclear Cardiology, vol. 20, no. 2, pp. 297-306, 2013.
52. G. Youssef, E. Leung, I. Mylonas et al., "The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience," Journal of Nuclear Medicine, vol. 53, no. 2, pp. 241-248, 2012.
53. N. Takeda, I. Yokoyama, Y. Hiroi et al., "Positron emission tomography predicted recovery of completeA-Vnodal dysfunction in a patient with cardiac sarcoidosis," Circulation, vol. 105, no. 9, pp. 1144-1145, 2002.
54. L. H. Brudin, S. O. Valind, C. G. Rhodes et al., "Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography," European Journal of Nuclear Medicine, vol. 21, no. 4, pp. 297-305, 1994.
55. P. J. Lewis, A. Salama, A. Alavi, C. A. Buchpiguel, A. Loessner, and S. M. Larson, "Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis," Journal of Nuclear Medicine, vol. 35, no. 10, pp. 1647-1649, 1994.
56. J. P. Smedema, V. Reenaers, and R. Geukens, "Images in cardiology. Cardiac sarcoidosis in a 60 year old woman.," Heart, vol. 92, article 688, 2006.
57. H. Koiwa, I. Tsujino, H. Ohira, K. Yoshinaga, N. Otsuka, and M. Nishimura, "Imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography: An autopsy case," Circulation, vol. 122, no. 5, pp. 535-536, 2010.
58. M. L. Bartlett, S. L. Bacharach, L. M. Voipio-Pulkki, and V. Dilsizian, "Artifactual inhomogeneities in myocardial PET and SPECT scans in normal subjects," Journal of Nuclear Medicine, vol. 36, no. 2, pp. 188-195, 1995.
59. R. J. Gropler, B. A. Siegel, K. J. Lee et al., "Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans," Journal of NuclearMedicine, vol. 31, no. 11, pp. 1749-1756, 1990.
60. M. Orii, K. Hirata, T. Tanimoto et al., "Early abnormality detected by speckle-tracking echocardiography in a patient with suspected cardiac sarcoidosis," Journal of Echocardiography, vol. 11, no. 2, pp. 69-71, 2013.
61. P. Iozzo, P. Chareonthaitawee, M. D. Terlizzi, D. J. Betteridge, E. Ferrannini, and P. G. Camici, "Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans," The American Journal of Physiology: Endocrinology and Metabolism, vol. 282, no. 5, pp. E1163-E1171, 2002.
62. A. H.Maurer, M. Burshteyn, L. P. Adler, J. P. Gaughan, and R. M. Steiner, "Variable cardiac 18FDG patterns seen in oncologic positron emission tomography computed tomography importance for differentiating normal physiology from cardiac and paracardiac disease," Journal of Thoracic Imaging, vol. 27, no. 4, pp. 263-268, 2012.
63. V. Ambrosini, M. Zompatori, L. Fasano et al., "18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: Results of a preliminary prospective study," Clinical Nuclear Medicine, vol. 38, no. 4, pp. e171-e177, 2013.
64. C. N. B. Harisankar, B. R. Mittal, K. L. Agrawal, M. L. Abrar, and A. Bhattacharya, "Utility of high fat and low carbohydrate diet in suppressingmyocardial FDG uptake," Journal of Nuclear Cardiology, vol. 18, no. 5, pp. 926-936, 2011.
65. G. Williams and G. M. Kolodny, "Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, lowcarbohydrate diet," The American Journal of Roentgenology, vol. 190, no. 2, pp. W151-w156, 2008.
66. J.A.Wisneski, E.W. Gertz, R. A. Neese, and M.Mayr, "Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans," The Journal of Clinical Investigation, vol. 79, no. 2, pp. 359-366, 1987.
67. K. Yoshinaga and N. Tamaki, "Imaging myocardial metabolism," Current Opinion in Biotechnology, vol. 18, no. 1, pp. 52-59, 2007.
68. Y. Choi, R. C. Brunken, R. A. Hawkins et al., "Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans," BioMed Research International 15 European Journal of Nuclear Medicine, vol. 20, no. 4, pp. 308-318, 1993.
69. E. Persson, "Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin)," Acta Medica Scandinavica, vol. 724, pp. 1-56, 1988.
70. M. Morooka, M. Moroi, K. Ito, and R. Minamimoto, "Heparin vs. long fasting method: Which inhibits the FDG myocardial physiological uptake more strongly?" Journal of Nuclear Medicine, vol. 54, supplement, p. 406P, 2013.
71. O. Israel, M. Weiler-Sagie, S. Rispler et al., "PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake," Journal of NuclearMedicine, vol. 48, no. 2, pp. 234-239, 2007.
72. E. Tadamura, M. Yamamuro, S. Kubo et al., "Multimodality imaging of cardiac sarcoidosis before and after steroid therapy," Circulation, vol. 113, no. 20, pp. e771-e773, 2006.
73. C. Pandya, R. C. Brunken, P. Tchou, P. Schoenhagen, and D. A. Culver, "Detecting cardiac involvement in sarcoidosis: A call for prospective studies of newer imaging techniques," European Respiratory Journal, vol. 29, no. 2, pp. 418-422, 2007.
74. A. Alavi, N. Gupta, J. Alberini et al., "Positron emission tomography imaging in nonmalignant thoracic disorders," Seminars in Nuclear Medicine, vol. 32, no. 4, pp. 293-321, 2002.
75. J. M. Chang, H. J. Lee, J. M. Goo, J. J. Lee, J. Chung, and J. Im, "False positive and false negative FDG-PET scans in various thoracic diseases," Korean Journal of Radiology, vol. 7, no. 1, pp. 57-69, 2006.
76. J. Lieberman, "Elevation of serum angiotension converting enzyme (ACE) level in sarcoidosis," The American Journal of Medicine, vol. 59, no. 3, pp. 365-372, 1975.
77. O. Selroos and C. Gronhagen-Riska, "Angiotensin converting enzyme, III: Changes in serum level as an indicator of disease activity in untreated sarcoidosis," Scandinavian Journal of Respiratory Diseases, vol. 60, no. 6, pp. 328-336, 1979.
78. S. Rothkrantz-Kos, M. P. van Dieijen-Visser, P. G. H. Mulder, and M. Drent, "Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis," Clinical Chemistry, vol. 49, no. 9, pp. 1510-1517, 2003.
79. M. W. Ziegenhagen, M. E. Rothe, M. Schlaak, and J. Müller-Quernheim, "Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis," European Respiratory Journal, vol. 21, no. 3, pp. 407-413, 2003.
80. M. Soussan, P. Brillet, H. Nunes et al., "Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis," Journal of Nuclear Cardiology, vol. 20, no. 1, pp. 120-127, 2013.
81. N. Y.Hamzeh, F. S.Wamboldt, and H.D.Weinberger, "Management of cardiac sarcoidosis in the United States: A Delphi study," Chest, vol. 141, no. 1, pp. 154-162, 2012.
82. F. P. DiFilippo and R. C. Brunken, "Do implanted pacemaker leads and ICD leads cause metal-related artifact in cardiac PET/CT?" Journal of Nuclear Medicine, vol. 46, no. 3, pp. 436-443, 2005.
83. P. Ghafarian, S. M. R. Aghamiri, M. R. Ay et al., "Is metal artefact reduction mandatory in cardiac PET/CT imaging in the presence of pacemaker and implantable cardioverter defibrillator leads?" European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 2, pp. 252-262, 2011.
84. J. Smedema, G. Snoep, M. P. G. Van Kroonenburgh et al., "Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands," Chest, vol. 128, no. 1, pp. 30-35, 2005.
85. A. Mavi, M. Urhan, J. Q. Yu et al., "Dual time point 18FFDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes," Journal of Nuclear Medicine, vol. 47, no. 9, pp. 1440-1446, 2006.
86. I. Kim, J. S. Lee, S. Kim et al., "Double-phase 18F-FDG PETCT for determination of pulmonary tuberculoma activity," European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 4, pp. 808-814, 2008.
87. J. Huang, A. L. Kindzelskii, and H. R. Petty, "Hexokinase translocation during neutrophil activation, chemotaxis, and phagocytosis: Disruption by cytochalasin D, dexamethasone, and indomethacin," Cellular Immunology, vol. 218, no. 1-2, pp. 95-106, 2002.
88. K. C. Pedley, G. E. Jones, M. Magnani, R. J. Rist, and R. J. Naftalin, "Direct observation of hexokinase translocation in stimulated macrophages," Biochemical Journal, vol. 291, no. 2, pp. 515-522, 1993.
89. Y. Umeda, Y. Demura, M. Morikawa et al., "Prognostic value of dual-time-point18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis," Respirology, vol. 16, no. 4, pp. 713-720, 2011.
90. Y. Ishida, K. Yoshinaga, M. Miyagawa et al., "Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society ofNuclear Cardiology Recommendations," Annals of Nuclear Medicine, vol. 28, no. 4, pp. 393-403, 2014.
91. M. D. Cerqueira, N. J. Weissman, V. Dilsizian et al., "Standardizedmyocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association," Circulation, vol. 105, pp. 539-542, 2002.
92. R. Boellaard, M. J. O'Doherty, W. A. Weber et al., "FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0," European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 181-200, 2010.
93. S. Schneider, A. Batrice, C. Rischpler, M. Eiber, T. Ibrahim, and S. G. Nekolla, "Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis : Implications for diagnosis, monitoring and treatment," European Heart Journal, vol. 35, no. 5, p. 312, 2014.
94. J. A. White, M. Rajchl, J. Butler, R. T. Thompson, F. S. Prato, and G. Wisenberg, "Active cardiac sarcoidosis first clinical experience of simultaneous positron emission tomographymagnetic resonance imaging for the diagnosis of cardiac disease," Circulation, vol. 127, no. 22, pp. e639-e641, 2013.
95. D. P. Sobic-Saranovic, I. T. Grozdic, J. Videnovic-Ivanov et al., "Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis," Clinical Nuclear Medicine, vol. 38, no. 7, pp. 516-521, 2013.
96. F. Nensa, K. Beiderwellen, P. Heusch, and A. Wetter, "Clinical applications of PET/MR: Current status and future perspectives," Diagnostic and Interventional Radiology, 2014.